Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 6, 2000, Pages 346-357

  Marcello, Susana ^a   Gladstein, Julio ^a   Tesone, Pedro ^a   Más, Rosa ^b  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Bezafibrate; Combination therapy; Dyslipidemia; Policosanol

Indexed keywords

BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; HUMAN; LIPID ANALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033921769     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80004-1     Document Type: Article

References (41)

1. 1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984; 251:351-364.
2. 2. Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: Primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
3. 3. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-362.
4. 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. 5. Sacks FM, Pfeffer MA, Moyé LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
6. 6. Tonkin A. A long-term intervention with pravastatin in ischemic disease (LIPID). Vortrag auf der 70 Jahrstagung der American Heart Association (AHA). 1997;12:11. Orlando.
7. 7. Shepherd S, Cobbe SM, Christopher G, et al, for the West of Scotland Prevention Study Group (WOSCOP). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
8. 8. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
9. 9. The International Lipid Information Bureau (ILIB). Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. 1995.
10. 10. Pyörala K, De Backer G, Graham I, et al, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur Heart J. 1994;15:1300-1331 and Atherosclerosis. 1994;110:121-161.
11. 11. Criqui MH, Heiss G, Cohn K, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
12. 12. Freedman DS, Gruchow HW, Anderson AJ, et al. Relation of triglyceride levels to coronary artery disease: The Milwaukee Cardiovascular Data Registry. Am J Epidemiol. 1988;127:1118-1130.
13. 13. Durrington PN. Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment. Atherosclerosis. 1998;139(Suppl 1):S1-S5.
14. 14. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther. 1998;79:205-230.
15. 15. Farmer JA, Gotto AM. Choosing the right lipid-regulating agent. A guide to selection. Drugs. 1996;52:649-661.
16. 16. Gaw A, Packard CJ, Shepherd J. Fibrates. In: Schettler G, Habennicht AJR, eds. Principles and Treatment of Lipoprotein Disorders. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag; 1994:325-348.
17. 17. Kumar S, Durrington PN, Bhatnagar D, Laing I. Suppression of nonesterified fatty acids to treat type A insulin resistance syndrome. Lancet. 1994;343:1073-1074.
18. 18. Shepherd J. The fibrates in clinical practice: Focus on micronised fenofibrate. Atherosclerosis. 1994;110(Suppl 1):S55-S63.
19. 19. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
20. 20. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J.
21. 21. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med. 1990;112:228-230.
22. 22. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-75.
23. 23. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination. Am J Med. 1994;96:401-407.
24. 24. Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 1987;33:539-576.
25. 25. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholaesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14:27-33.
26. 26. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
27. 27. Canetti M, Moreira M, Más R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res. 1995;15:159-165.
28. 28. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with disturbances in serum biochemical indicators of hepatic function. Curr Ther Res. 1996;57:568-577.
29. 29. Ortensi G, Gladstein H, Valli H, Tesone PA. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 1997;58:390-401.
30. 30. Benítez M, Romero C, Más R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res. 1997;58:859-867.
31. 31. Más R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther. 1999;65: 6-14.
32. 32. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
33. 33. Crespo N, Alvarez R, Más R, et al. Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study. Curr Ther Res. 1997;58:44-51.
34. 34. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
35. 35. Menéndez R, Arruzazabala L, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr. 1997;77:923-932.
36. 36. Castaño G, Más R, Tabares I, et al. Estudio comparativo del policosanol, gemfibrozil y la terapia combinada policosanol-gemfibrozil en el tratamiento de la hipercolesterolemia tipo II. Rev. CENIC Cien Biol. 1998;29:17-23.
37. 37. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin Chem. 1981;27:838-841.
38. 38. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
39. 39. Menéndez R, Fraga V, Amor AM, et al. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav. 1999;67:1-7.
40. 40. Menéndez R, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. In press.
41. 41. Barter PJ, Rye KA, Clay MA, et al. Antiatherogenic effects of high-density lipoproteins: Mechanism. Atherosclerosis XI. Proceedings of the XIth International Symposium on Atherosclerosis, October 5-9, 1997; Paris, France; 811-816.